
CryoPort (CYRX) Stock Forecast & Price Target
CryoPort (CYRX) Analyst Ratings
Bulls say
CryoPort Inc. demonstrated robust financial growth with a total revenue of $44 million, reflecting a 15% increase in constant currency terms, which shows an uptick from the previous quarter's 14% growth. The ongoing rise in gene therapy programs, particularly in oncology and rare diseases, supports a favorable outlook as the market becomes increasingly receptive to innovative cell and gene therapies. The anticipated increase in both commercial revenue and clinical trial activity indicates a stable growth trajectory, reinforcing positive sentiment around the company's future prospects.
Bears say
CryoPort Inc. faces a challenging outlook as revenue growth in its Life Sciences Services segment has slowed, with a 16% increase in the latest quarter, down from 21% in the previous quarter, indicating potential long-term declining trends. The company's adjusted EBITDA margin remains in negative territory at (1.5%), which, despite an annual improvement, fell short of market expectations, further suggesting potential profitability issues. Additionally, the bear case scenarios highlight concerns over slowing demand for critical products and a decline in the approval of cell and gene therapies, which may adversely impact future growth and margins.
This aggregate rating is based on analysts' research of CryoPort and is not a guaranteed prediction by Public.com or investment advice.
CryoPort (CYRX) Analyst Forecast & Price Prediction
Start investing in CryoPort (CYRX)
Order type
Buy in
Order amount
Est. shares
0 shares